Holen Sie sich die Stockscreener-App
1.01
0.98%
-0.01
Schlusskurs vom Vortag:
$1.02
Offen:
$1.02
24-Stunden-Volumen:
37,962
Relative Volume:
0.30
Marktkapitalisierung:
$44.44M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-31.39M
KGV:
-1.2024
EPS:
-0.84
Netto-Cashflow:
$-18.45M
1W Leistung:
-9.82%
1M Leistung:
-29.86%
6M Leistung:
+30.66%
1J Leistung:
+0.50%
1-Tages-Spanne:
$0.9999
$1.03
1-Wochen-Bereich:
$0.9319
$1.10
52-Wochen-Spanne:
$0.5116
$2.45
Quince Therapeutics Inc Stock (QNCX) Company Profile
Firmenname
Quince Therapeutics Inc
Sektor
Branche
Telefon
415-910-5717
Adresse
611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO
Vergleichen Sie QNCX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
QNCX
Quince Therapeutics Inc
|
1.01 | 44.44M | 0 | -31.39M | -18.45M | -0.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.49 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.91 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
605.38 | 36.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
230.93 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.84 | 25.73B | 3.81B | -644.79M | -669.77M | -6.24 |
Quince Therapeutics Inc Stock (QNCX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-24 | Eingeleitet | Oppenheimer | Outperform |
Quince Therapeutics Inc Aktie (QNCX) Neueste Nachrichten
Quince Therapeutics, Inc. (NASDAQ:QNCX) Given Average Rating of “Buy” by Analysts - Defense World
Quince Therapeutics to Present at Jones Healthcare and Technology Innovation Conference - BioSpace
Rare Disease Biotech Quince to Unveil Latest Developments at Major Healthcare Conference - Stock Titan
Quince Therapeutics (QNCX) Expected to Announce Earnings on Monday - Defense World
Oppenheimer Initiates Coverage on Quince Therapeutics (NASDAQ:QNCX) - MarketBeat
D. Boral Capital Issues Pessimistic Forecast for Quince Therapeutics (NASDAQ:QNCX) Stock Price - The AM Reporter
Analysts Are Bullish on Top Healthcare Stocks: Quince Therapeutics (QNCX), Lucid Diagnostics (LUCD) - The Globe and Mail
Quince Therapeutics (NASDAQ:QNCX) Price Target Lowered to $4.00 at D. Boral Capital - Defense World
Quince Therapeutics Reports 2024 Financial Results and Trial Progress - TipRanks
Quince Therapeutics stock target cut to $4 from $12, maintains buy By Investing.com - Investing.com South Africa
Quince Therapeutics stock target cut to $4 from $12, maintains buy - Investing.com
Quince Therapeutics (NASDAQ:QNCX) Now Covered by Oppenheimer - Defense World
Quince Therapeutics Existing Cash Position To Provide Operating Runway Through Phase 3 Topline Results Into 2026 - MarketScreener
Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results - Business Wire
Oppenheimer sets $10 target for Quince Therapeutics stock By Investing.com - Investing.com South Africa
Oppenheimer Initiates Coverage of Quince Therapeutics (QNCX) with Outperform Recommendation - Nasdaq
Oppenheimer Initiates Quince Therapeutics at Outperform -March 24, 2025 at 07:46 am EDT - Marketscreener.com
Oppenheimer sets $10 target for Quince Therapeutics stock - Investing.com
Quince Therapeutics (QNCX) Projected to Post Earnings on Monday - Defense World
Analysts Set Quince Therapeutics, Inc. (NASDAQ:QNCX) Target Price at $9.50 - Defense World
Quince Therapeutics (NASDAQ:QNCX) versus IN8bio (NASDAQ:INAB) Critical Contrast - Defense World
Market Momentum Report: Quince Therapeutics Inc (QNCX)’s Negative Close at 1.41 - The Dwinnex
Vaxart (NASDAQ:VXRT) vs. Quince Therapeutics (NASDAQ:QNCX) Critical Comparison - Armenian Reporter
Ataxia Treatment Market Size in the 7MM is expected to grow - openPR
Financial Survey: Quince Therapeutics (NASDAQ:QNCX) & Vaxart (NASDAQ:VXRT) - Defense World
Head to Head Comparison: Quince Therapeutics (NASDAQ:QNCX) and Quantum Genomics Société Anonyme (OTCMKTS:QNNTF) - Defense World
Spotlight On Fractyl Health And Two Other Intriguing Penny Stocks - Simply Wall St
Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives $9.50 Average Price Target from Analysts - Defense World
Quince Therapeutics, Inc. (NASDAQ:QNCX) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
D. Boral Capital Reiterates "Buy" Rating for Quince Therapeutics (NASDAQ:QNCX) - MarketBeat
Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia - Business Wire
Quince Therapeutics secures USPTO nod for A-T treatment patent - MSN
D. Boral Capital Reaffirms “Buy” Rating for Quince Therapeutics (NASDAQ:QNCX) - Defense World
Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - Marketscreener.com
Rare Disease Pioneer Quince Therapeutics Takes Center Stage at Major Healthcare Conference - Stock Titan
Quince Therapeutics secures USPTO nod for A-T treatment patent By Investing.com - Investing.com Australia
Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia - Business Wire
Patent Victory: Quince's Rare Disease Treatment Gets Dual-Layer Protection Until 2036 - Stock Titan
Ataxia Telangiectasia Market on Track for Major Expansion by 2032, According to DelveInsight | Acasti Pharma Inc., IntraBio Inc - The Globe and Mail
Earnings Coming in Better-Than-Expected As Peak Season Begins - The Globe and Mail
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Meta Platforms Is Surging on Q4 Earnings. Is Meta Stock a Buy, Sell, or Hold for 2025? - The Globe and Mail
Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives $9.50 Average PT from Brokerages - Defense World
Earnings To Watch: Kirby (KEX) Reports Q4 Results Tomorrow - The Globe and Mail
Quince Therapeutics to Host Investor Webinar on February 7, 2025 Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia - Business Wire
Quince Therapeutics, Inc. Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia - Marketscreener.com
Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia - Business Wire
Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives $9.50 Consensus Target Price from Brokerages - MarketBeat
Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board - Business Wire
BioXcel Therapeutics expands board, appoints new director - Investing.com
Geode Capital Management LLC Purchases 66,170 Shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) - Defense World
Finanzdaten der Quince Therapeutics Inc-Aktie (QNCX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.98%
5.78%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):